Advancing Cell and Gene Therapy Development Through Innovation and Collaboration

At Advanced Therapies Week 2025, Fresenius Kabi representatives Jenny Stjernberg (Commercial Director for Therapeutic Apheresis and Cell Therapy in Europe) and Alaina Schlinker (Director of Cell Therapy Field Application Support) joined AT-TV to discuss how their technologies are addressing critical challenges in cell therapy manufacturing.

Fresenius Kabi’s platforms, including the Lovo and Cue Cell Processing Systems, are built with flexibility in mind—designed to adapt to diverse manufacturing needs and integrate seamlessly with other industry-leading technologies. The systems support a range of unit operations, from cell concentration and washing to formulation and fill-finish, all configurable to customer requirements.

Key collaborations with technologies like the Wilson Wolf G-Rex bioreactor, Ori Biotech’s manufacturing system, and Cellular Origins’ automation solutions position Fresenius Kabi as a versatile partner for companies scaling from small-batch treatments to high-volume production. These partnerships ensure that as therapy developers grow, they can scale up without having to overhaul their manufacturing platforms.

The company continues to invest in innovation, including a forthcoming Lovo 4.0 software update, which will enhance cell concentration targeting, final volume reduction, and real-time data monitoring. Additionally, they are developing large-volume processing capabilities, supporting volumes up to 50 liters—essential for scaling allogeneic therapies.

Looking ahead to 2030, Fresenius Kabi anticipates launching further advancements currently in development, aimed at enhancing efficiency, scalability, and automation in cell therapy manufacturing.